期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

糖尿病肾病患者残余蛋白尿治疗新进展 被引量：6

原文传递
导出
摘要 蛋白尿不仅是糖尿病肾病（DN）的监测指标，也是其重要的可调节指标，控制蛋白尿的排泄与肾脏的预后有着紧密联系。治疗后的蛋白尿下降程度和残余蛋白尿同初始蛋白尿一样重要，是肾脏预后的重要标志，所谓残余蛋白尿，目前没有公认的定义，依据诸多学者的表述是指即使充分使用肾素血管紧张素系统（RAS）阻滞剂，蛋白尿水平仍旧无法下降甚至控制到正常水平，
作者 黄艳 陈海冰
机构地区 上海交通大学附属第六人民医院内分泌代谢科上海市糖尿病研究所上海市糖尿病重点实验室上海市糖尿病临床医学中心
出处 《中华医学杂志》 CAS CSCD 北大核心 2011年第44期3158-3160,共3页 National Medical Journal of China
基金 国家自然科学基金（81070649）
关键词 糖尿病肾病患者 蛋白尿 残余 治疗 肾素血管紧张素系统 监测指标 可调节 阻滞剂
分类号 R587.2 [医药卫生—内分泌]
  • 相关文献

参考文献27

  • 1林洪丽,张靖华.RAS阻断剂在蛋白尿治疗中的应用[J].临床肾脏病杂志,2010(7):330-331. 被引量：2
  • 2Kelly DJ,Zhang Y,Moe G,et al.Aliskiren,a novel renin inhibitor,is renoprotective in a model of advanced diabetic nephropathy in rats.Diabetologia,2007,50:2398-2404.
  • 3Parving HH,Persson F,Lewis JB,et al.Aliskiren combined with losartan in type 2 diabetes and nephropathy.N Engl J Med,2008,358:2433-2446.
  • 4Dong YF,Liu L,Lai ZF,et al.Aliskiren enhances protective effects of valsartan against type 2 diabetic nephropathy in mice.J Hypertens,2010,28:1554-1565.
  • 5Diaz VA,Mainous AG,Carek PJ,et al.The association of vitamin D deficiency and insufficiency with diabetic nephropathy:implications for health disparities.J Am Board Fam Med,2009,22:521-527.
  • 6de Zeeuw D,Agarwal R,Amdahl M,et al.Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study):a randomised controlled trial Lancet,2010,376:1543-1551.
  • 7Zhang Z,Sun L,Wang Y,et al Renoprotective role of the vitamin D receptor in diabetic nephropathy.Kidney Int,2008,73:163-171.
  • 8Zhang Z,Zhang Y,Ning G,et al.Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy:blockade of compensatory renin increase.Proc Natl Acad Sci U S A,2008,105:15896-15901.
  • 9Sasaki T,Kurata H,Nomura K,et al.Amelioration of proteinuria with pravastatin in hypercholesterolemic patients with diabetes mellitus.Jpn J Med,1990,29:156-163.
  • 10Fujii M,Inoguchi T,Maeda Y,et al Pitavastatin ameliorates albuminuria and renal mesangial expansion by downregulating NOX4 in db/db mice.Kidney Int,2007,72:473-480.

二级参考文献45

  • 1廖琳,周新丽,王熙宁,赵家军.前列腺素E_1治疗糖尿病下肢血管病变疗效观察[J].山东医药,2005,45(7):40-41. 被引量：13
  • 2曲勇,潘振宇,辛颖,杨明,韩文霞,邢海燕,廖琳.前列腺素E1对糖尿病肾病大鼠肾脏细胞凋亡的影响及其机制的研究[J].细胞与分子免疫学杂志,2006,22(6):774-776. 被引量：16
  • 3宋利格,李颖,周筠,陈亚青,李红,张秀珍.α-硫辛酸对糖尿病周围神经病变的疗效[J].中华内分泌代谢杂志,2007,23(2):166-167. 被引量：92
  • 4Seligman BG, Biolo A, Polanczyk CA, et al. Increased plasma levels of endothelin 1 and yon Willebrand factor in patients with type 2 diabetes and dyslipidemia. Diabetes Care, 2000,23 : 1395-1400.
  • 5Coen DA. Endothelial dysfunction in diabetic nephropathy: state of the art and potential significance for non-diabetic renal disease. Nephrol Dial Translant, 2004,19:778-781.
  • 6Akasaka N, Yamazaki K, Ishikawa M, et al. Lipo-prostaglandin El is absorbed by vascular smooth muscle cells and may enhance re-endothelialization of vein grafts. Cardiovasc Surg (Torino), 2002, 43.. 869-875.
  • 7Ergul A, Johansen JS, Stromhaug C, et al. Vascular dysfunction of venous bypass conduits is mediated by reactive oxygen species in diabetes: role of endothelinl. Pharmacol Exp Ther,2005,313 : 70-77.
  • 8Remuzzi G, Bertani T. Pathophysilogy of progressive nephropathies. N Engl J Med,1998,39:1448.
  • 9Dominguec JH,Tang N,Xu W,et al. Studies of renal injury 19: Lipid induced nephropathy in type Ⅱ. Kidcy Int,2002, 3:196-198.
  • 10Huang JS, Guh JY, Hung WC, el al. Role of the Janus kinase(JAK)/signal transduclets and activators of transcription ( STAT ) cascade in advanced glycation end product induced cellular mitogenesls in NKK-49F cells. Biechem J,1999,342(Pt1) :231-238.

共引文献55

同被引文献36

  • 1全国eGFR课题协作组.MDRD方程在我国慢性肾脏病患者中的改良和评估[J].中华肾脏病杂志,2006,22(10):589-595. 被引量：708
  • 2Schmidt MI, Hadji-Georgopoulos A, Rendell M,et al. Thedawn phenomenon, an early morning glucose rise : implicationsfor diabetic intraday blood glucose variation [ J]. DiabetesCare,1981,4(6) ;579-585.
  • 3Sung JY,Park SB,Liu YT,et al. Progressive axonal dysfunc-tion precedes development of neuropathy in type 2 diabetes[J]. Diabetes,2012,61 (6) :1592-1598.
  • 4Rybicka M,Krysiak R,Okopien B. The dawn phenomenon andthe Somogyi effect-two phenomena of morning hyperglycae-mia [Jj.Endokrynol Pol,2011,62(3) :276-284.
  • 5Navarro-González JF,Mora-Fernández C,Muros de Fuentes M,et al.Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy[J].Nat Rev Nephrol,2011;7(6):327-40.
  • 6Fitzpatrick DC,Sheerin DV,Wolf BR,et al.A randomized,prospective study comparing intertrochanteric hip fracture fixation with the dynamic hip screw and the dynamic helical hip system in a community practice[J].Iowa Orthop J,2011;31(2):166-72.
  • 7Azar D,Mohsen J,Shila K.Effects of antenatal corticosteroids on maternal serum indicators of infection in women at risk for preterm delivery:a randomized trial comparing betamethasone and dexamethasone[J].J Res Med Sci:Official J Isfahan Uni Med Sci,2012;17(10):911-7.
  • 8Mega C,de Lemos ET,Vala H,et al.Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes(Zucker Diabetic Fatty Rat)[J].Exp Diabet Res,2011;16(20):92.
  • 9Hunziker S,Hugle T,Schuchardt K,et al.The value of serum procalcitonin level for differentiation of infections from noninfectious causes of fever after orthopedic surgery[J].Bone Joint Surg,2010;92(1):138-48.
  • 10Cheng T,Zhang G,Zhang X.Review:minimally invasive versus conventional dynamic hip screw fixation in elderly patients with intertrochanteric fractures:a systematic review and meta-analysis[J].Surg Innov,2011;18(2):99-105.

引证文献6

二级引证文献202

中华医学杂志
2011年 第44期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部